STAT3 and breast cancer: Given these different growth patterns, we also examined how perturbation in phosphotyrosine-dependent ShcA signalling impacts the STAT1 and STAT3 activation status of mammary tumours that display immune surveillance (MT/Shc2F/2F) versus suppression (MT/ShcA+/+ and MT/Shc313F/313F) phenotypes.